


Figure 1 A

A549 HCC827 NCI-H1975

p-EGFR



A549 HCC827 NCI-H1975

EGFR




Figure 1 A

A549 HCC827 NCI-H1975

PD-L1




A549 HCC827 NCI-H1975

GAPDH



Figure 2A



A549
GAPDH





Figure 2B



EGF:40 ng/ml	-	+	+	+	+
CyH (μ M)	-	-	6.25	12.5	25


A549
EGFR



Figure 2B

EGF:40 ng/ml	-	+	+	+	+
CyH (μM)	-	-	6.25	12.5	25

A549
PD-L1



EGF:40 ng/ml	-	+	+	+	+
CyH (μM)	-	-	6.25	12.5	25

A549
GAPDH




Figure 2B





Figure 2B

CyH (μM) - 6.25 12.5 25

HCC827
PD-L1



CyH (μM) - 6.25 12.5 25

HCC827
GAPDH




Figure 2B






Figure 2B

CyH (μM) - 6.25 12.5 25

NCI-1975
PD-L1



CyH (μM) - 6.25 12.5 25

NCI-1975
GAPDH





Figure 4A

CyH (12.5 μ M)	-	-	+	+
Gefitinib (5 μ M)	-	+	-	+

HCC827
p-EGFR



CyH (12.5 μ M)	-	-	+	+
Gefitinib (5 μ M)	-	+	-	+

HCC827
EGFR




Figure 4A

CyH (12.5 μ M)	-	-	+	+
Gefitinib (5 μ M)	-	+	-	+

HCC827
PD-L1



CyH (12.5 μ M)	-	-	+	+
Gefitinib (5 μ M)	-	+	-	+

HCC827
GAPDH




Figure 4B






Figure 4B

CyH (12.5 μ M)	-	-	+	+
Gefitinib (5 μ M)	-	+	-	+

NCI-H1975
PD-L1



CyH (12.5 μ M)	-	-	+	+
Gefitinib (5 μ M)	-	+	-	+

NCI-1975
GAPDH



Figure 6A






Figure 6A





Figure 6A






Figure 6B



EGF (40 ng/ml)	-	+	+	+	+
CyH (μM)	-	-	6.25	12.5	25

A549
JAK3






Figure 6B

EGF (40 ng/ml)	-	+	+	+	+
CyH (μM)	-	-	6.25	12.5	25



EGF (40 ng/ml)	-	+	+	+	+
CyH (μM)	-	-	6.25	12.5	25



EGF (40 ng/ml)	-	+	+	+	+
CyH (μM)	-	-	6.25	12.5	25





Figure 6B

EGF (40 ng/ml)	-	+	+	+	+
CyH (μM)	-	-	6.25	12.5	25

A549
STAT3



EGF (40 ng/ml)	-	+	+	+	+
CyH (μM)	-	-	6.25	12.5	25

A549
GAPDH





Figure 6C

CyH (μM) 0 6.25 12.5 25

HCC827
p-JAK3



CyH (μM) 0 6.25 12.5 25

HCC827
JAK3




Figure 6C





Figure 6C




Figure 6D







Figure 6D

CyH (μM) 0 6.25 12.5 25

NCI-1975
STAT1



CyH (μM) 0 6.25 12.5 25

NCI-1975
p-STAT3




Figure 6D





Figure 6E

CyH (12.5 μ M)	-	-	+	+
Gefitinib (5 μ M)	-	+	-	+

NCI-H1975
p-JAK3




Figure 6E

CyH (12.5 μ M)	-	-	+	+
Gefitinib (5 μ M)	-	+	-	+

NCI-H1975
JAK3



Figure 6E

CyH (12.5 μ M)	-	-	+	+
Gefitinib (5 μ M)	-	+	-	+

NCI-H1975
p-STAT1




Figure 6E

CyH (12.5 μ M)	-	-	+	+
Gefitinib (5 μ M)	-	+	-	+

NCI-H1975
STAT1



Figure 6E

CyH (12.5 μ M)	-	-	+	+
Gefitinib (5 μ M)	-	+	-	+

NCI-H1975
p-STAT3




Figure 6E

CyH (12.5 μ M)	-	-	+	+
Gefitinib (5 μ M)	-	+	-	+

NCI-H1975
STAT3




Figure 6E

CyH (12.5 μ M)	-	-	+	+
Gefitinib (5 μ M)	-	+	-	+

NCI-H1975
GAPDH

